Seok-Joong Yun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1310850/publications.pdf

Version: 2024-02-01

		331538	302012
139	2,207	21	39
papers	citations	h-index	g-index
139	139	139	3313
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer. Prostate International, 2022, 10, 1-6.	1.2	5
2	Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone. Investigative and Clinical Urology, 2022, 63, 238.	1.0	3
3	Expression of RPL9 predicts the recurrence of non-muscle invasive bladder cancer with BCG therapy. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	2
4	Induction of apoptotic cell death in human bladder cancer cells by ethanol extract of <i>Zanthoxylum schinifolium</i> leaf, through ROS-dependent inactivation of the PI3K/Akt signaling pathway. Nutrition Research and Practice, 2022, 16, 330.	0.7	3
5	TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer. Cancer Letters, 2021, 499, 137-147.	3.2	42
6	A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 237.e21-237.e29.	0.8	12
7	Prominence of urinary biomarkers for bladder cancer in the COVID-19 era: From the commercially available to new prospective candidates. Investigative and Clinical Urology, 2021, 62, 500.	1.0	4
8	Trends in End-of-Life Resource Utilization and Costs among Prostate Cancer Patients from 2006 to 2015: A Nationwide Population-Based Study. World Journal of Men?s Health, 2021, 39, 158.	1.7	6
9	A high basal metabolic rate is an independent predictor of stone recurrence in obese patients. Investigative and Clinical Urology, 2021, 62, 195.	1.0	4
10	Expression of phosphorylated p21-activated kinase 4 is associated with aggressive histologic characteristics and poor prognosis in patients with surgically treated renal cell carcinoma. Investigative and Clinical Urology, 2021, 62, 399.	1.0	2
11	A Molecular Signature Determines the Prognostic and Therapeutic Subtype of Non-Muscle-Invasive Bladder Cancer Responsive to Intravesical Bacillus Calmette-Guérin Therapy. International Journal of Molecular Sciences, 2021, 22, 1450.	1.8	6
12	Role of Exosomal miRNA in Bladder Cancer: A Promising Liquid Biopsy Biomarker. International Journal of Molecular Sciences, 2021, 22, 1713.	1.8	36
13	Betulinic Acid Restricts Human Bladder Cancer Cell Proliferation In Vitro by Inducing Caspase-Dependent Cell Death and Cell Cycle Arrest, and Decreasing Metastatic Potential. Molecules, 2021, 26, 1381.	1.7	15
14	The Prognosis and Oncological Predictor of Urachal Carcinoma of the Bladder: A Large Scale Multicenter Cohort Study Analyzed 203 Patients With Long Term Follow-Up. Frontiers in Oncology, 2021, 11, 683190.	1.3	10
15	Collagen typeÂVlâ€Î±1 and 2 repress the proliferation, migration and invasion of bladder cancer cells. International Journal of Oncology, 2021, 59, .	1.4	21
16	Effect of pre-operative internal obturator muscle mass index in MRI on biochemical recurrence of prostate cancer patients after radical prostatectomy: a multi-center study. BMC Urology, 2021, 21, 85.	0.6	1
17	Microbiome of Genitourinary Tumors: Especially in Prostate Cancer and Kidney Cancer. The Korean Journal of Urological Oncology, 2021, 19, 136-147.	0.1	O
18	Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer. Investigative and Clinical Urology, 2021, 62, 340.	1.0	14

#	Article	IF	CITATIONS
19	Nutritional status assessed by the Controlling Nutritional Status (CONUT) score as a predictor of recurrence of urolithiasis. Investigative and Clinical Urology, 2021, 62, 553.	1.0	2
20	The prognostic value of the pretreatment serum albumin to globulin ratio for predicting adverse pathology in patients undergoing radical prostatectomy for prostate cancer. Investigative and Clinical Urology, 2021, 62, 545.	1.0	6
21	Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression. International Journal of Molecular Sciences, 2021, 22, 12756.	1.8	7
22	A Low Geriatric Nutritional Risk Index is Associated with Aggressive Pathologic Characteristics and Poor Survival after Nephrectomy in Clear Renal Cell Carcinoma: A Multicenter Retrospective Study. Nutrition and Cancer, 2020, 72, 88-97.	0.9	19
23	The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 187-196.	1.2	24
24	Induction of Apoptosis by Coptisine in Hep3B Hepatocellular Carcinoma Cells through Activation of the ROS-Mediated JNK Signaling Pathway. International Journal of Molecular Sciences, 2020, 21, 5502.	1.8	15
25	The immunostimulatory effect of indole-6-carboxaldehyde isolated from <i>Sargassum thunbergii</i> (Mertens) Kuntze in RAW 264.7 macrophages. Animal Cells and Systems, 2020, 24, 233-241.	0.8	6
26	Evaluation of the In Vitro and In Vivo Antitumor Efficacy of Peanut Sprout Extracts Cultivated with Fermented Sawdust Medium Against Bladder Cancer. Applied Sciences (Switzerland), 2020, 10, 8758.	1.3	3
27	Tumor heterogeneity in muscle-invasive bladder cancer. Translational Andrology and Urology, 2020, 9, 2866-2880.	0.6	11
28	Characteristics of Renal Cell Carcinoma Harboring TPM3-ALK Fusion. Yonsei Medical Journal, 2020, 61, 262.	0.9	6
29	Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting. Investigative and Clinical Urology, 2020, 61, 19.	1.0	6
30	A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. Oncology Letters, 2020, 19, 476-486.	0.8	9
31	A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone. Investigative and Clinical Urology, 2020, 61, 411.	1.0	7
32	The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma. Translational Cancer Research, 2020, 9, 6609-6623.	0.4	1
33	Glucose-derived acetate and ACSS2 as key players in cisplatin resistance in bladder cancer. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 413-421.	1.2	26
34	Anti-Proliferative and Pro-Apoptotic Effects of Licochalcone A through ROS-Mediated Cell Cycle Arrest and Apoptosis in Human Bladder Cancer Cells. International Journal of Molecular Sciences, 2019, 20, 3820.	1.8	46
35	For Physicians Managing Voiding Dysfunction, Improving the Detection Rate of Early Prostate Cancer and Discrimination From Benign Prostatic Hyperplasia, in a Molecular Biomarker Aspects. International Neurourology Journal, 2019, 23, 5-12.	0.5	6
36	Isorhamnetin Induces Cell Cycle Arrest and Apoptosis Via Reactive Oxygen Species-Mediated AMP-Activated Protein Kinase Signaling Pathway Activation in Human Bladder Cancer Cells. Cancers, 2019, 11, 1494.	1.7	33

#	Article	IF	Citations
37	Citrus unshiu peel suppress the metastatic potential of murine melanoma B16F10 cells in vitro and in vivo. Phytotherapy Research, 2019, 33, 3228-3241.	2.8	8
38	Necrotizing fasciitis associated with sorafenib treatment. IDCases, 2019, 18, e00611.	0.4	4
39	National practice patterns and direct medical costs for prostate cancer in Korea across a 10 year period: a nationwide population-based study using a national health insurance database. BMC Health Services Research, 2019, 19, 408.	0.9	11
40	Protective effect of diphlorethohydroxycarmalol against oxidative stress-induced DNA damage and apoptosis in retinal pigment epithelial cells. Cutaneous and Ocular Toxicology, 2019, 38, 298-308.	0.5	20
41	Twenty-four-hour urine osmolality as a representative index of adequate hydration and a predictor of recurrence in patients with urolithiasis. International Urology and Nephrology, 2019, 51, 1129-1135.	0.6	8
42	Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, e704-e711.	0.9	12
43	ZNF492 and GPR149 methylation patterns as prognostic markers for clear cell renal cell carcinoma: Array‑based DNA methylation profiling. Oncology Reports, 2019, 42, 453-460.	1.2	6
44	Urinary cellâ€free microRNA biomarker could discriminate bladder cancer from benign hematuria. International Journal of Cancer, 2019, 144, 380-388.	2.3	30
45	Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 86-96.	0.8	11
46	Methylation Signature for Prediction of Progression Free Survival in Surgically Treated Clear Cell Renal Cell Carcinoma. Journal of Korean Medical Science, 2019, 34, e144.	1.1	17
47	Medical Travel among Non-Seoul Residents to Seek Prostate Cancer Treatment in Medical Facilities of Seoul. Cancer Research and Treatment, 2019, 51, 53-64.	1.3	10
48	Trends in clinical, operative, and pathologic characteristics of surgically treated renal mass in a Korean center: A surgical series from 1988 through 2015. Investigative and Clinical Urology, 2019, 60, 184.	1.0	2
49	Predictive Molecular and Protein Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer. The Korean Journal of Urological Oncology, 2019, 17, 81-87.	0.1	0
50	Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 274-280.	0.9	8
51	Induction of Apoptosis by <i>Citrus unshiu</i> Peel in Human Breast Cancer MCF-7 Cells: Involvement of ROS-Dependent Activation of AMPK. Biological and Pharmaceutical Bulletin, 2018, 41, 713-721.	0.6	17
52	Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study. Urology, 2018, 111, 145-150.	0.5	5
53	<i>CDC6</i> mRNA Expression Is Associated with the Aggressiveness of Prostate Cancer. Journal of Korean Medical Science, 2018, 33, e303.	1.1	19
54	Prognostic Impact of Nutritional Status Assessed by the Controlling Nutritional Status (CONUT) Score in Patients with Surgically Treated Renal Cell Carcinoma. Nutrition and Cancer, 2018, 70, 886-894.	0.9	18

#	Article	IF	CITATIONS
55	Bilateral Obstructive Uropathy Caused by Congenital Bladder Diverticulum Presenting as Hypertensive Retinopathy. Journal of Korean Medical Science, 2018, 33, e54.	1.1	3
56	The p21-activated kinase 4-Slug transcription factor axis promotes epithelialâ^'mesenchymal transition and worsens prognosis in prostate cancer. Oncogene, 2018, 37, 5147-5159.	2.6	41
57	Identification of differentially expressed miRNAs and miRNA-targeted genes in bladder cancer. Oncotarget, 2018, 9, 27656-27666.	0.8	20
58	The Role of MicroRNAs in Oncogenesis and Progression of Prostate Cancer. The Korean Journal of Urological Oncology, 2018, 16, 1-6.	0.1	1
59	Generation of Whole-Genome Sequencing Data for Comparing Primary and Castration-Resistant Prostate Cancer. Genomics and Informatics, 2018, 16, 71-74.	0.4	1
60	Precision Medicine in Castration-Resistant Prostate Cancer. The Korean Journal of Urological Oncology, 2018, 16, 97-102.	0.1	0
61	Metabolic Characteristics and Risks Associated with Stone Recurrence in Korean Young Adult Stone Patients. Journal of Endourology, 2017, 31, 806-811.	1.1	7
62	Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses. Journal of Virology, 2017, 91, .	1.5	10
63	HSP70-1 is required for interleukin-5-induced angiogenic responses through eNOS pathway. Scientific Reports, 2017, 7, 44687.	1.6	30
64	Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness. Clinical Genitourinary Cancer, 2017, 15, 450-454.	0.9	14
65	Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status. Oncology Letters, 2017, 14, 3817-3824.	0.8	29
66	Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia. Journal of Urology, 2017, 198, 1340-1345.	0.2	2
67	Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer. Oncology Letters, 2017, 14, 2468-2474.	0.8	6
68	Chronological Trends in Clinical and Urinary Metabolic Features over 20 Years in Korean Urolithiasis Patients. Journal of Korean Medical Science, 2017, 32, 1496.	1.1	7
69	Impact of the ASA Physical Status Score on Adjuvant Chemotherapy Eligibility and Survival of Upper Tract Urothelial Carcinoma Patients: a Multicenter Study. Journal of Korean Medical Science, 2017, 32, 335.	1.1	10
70	The Trend of Uro-Oncologist About Blood Test and Imaging Studies for the Diagnosis of Biochemical Recurrence in Korea. The Korean Journal of Urological Oncology, 2017, 15, 131-136.	0.1	0
71	Can lymphovascular invasion replace the prognostic value of lymph node involvement in patients with upper tract urothelial carcinoma after radical nephroureterectomy?. Canadian Urological Association Journal, 2016, 10, 229.	0.3	1
72	How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?. Investigative and Clinical Urology, 2016, 57, S44.	1.0	19

#	Article	IF	CITATIONS
73	Impact of Young Age at Diagnosis on Survival in Patients with Surgically Treated Renal Cell Carcinoma: a Multicenter Study. Journal of Korean Medical Science, 2016, 31, 1976.	1.1	20
74	DUSP1 induces paclitaxel resistance through the regulation of p-glycoprotein expression in human ovarian cancer cells. Biochemical and Biophysical Research Communications, 2016, 478, 403-409.	1.0	15
75	Increased Expression of Herpes Virus-Encoded hsv1-miR-H18 and hsv2-miR-H9-5p in Cancer-Containing Prostate Tissue Compared to That in Benign Prostate Hyperplasia Tissue. International Neurourology Journal, 2016, 20, 122-130.	0.5	12
76	Virus encoded circulatory miRNAs for early detection of prostate cancer. BMC Urology, 2015, 15, 116.	0.6	3
77	Preoperative Underweight Patients with Upper Tract Urothelial Carcinoma Survive Less after Radical Nephroureterectomy. Journal of Korean Medical Science, 2015, 30, 1483.	1.1	16
78	Urinary Nucleic Acid <i>TSPAN13</i> -to- <i>S100A9</i> Ratio as a Diagnostic Marker in Prostate Cancer. Journal of Korean Medical Science, 2015, 30, 1784.	1.1	7
79	Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics. Journal of Korean Medical Science, 2015, 30, 937.	1.1	8
80	The c-MET Network as Novel Prognostic Marker for Predicting Bladder Cancer Patients with an Increased Risk of Developing Aggressive Disease. PLoS ONE, 2015, 10, e0134552.	1.1	14
81	Clinical Implications and Prognostic Values of <i>Prostate Cancer Susceptibility Candidate </i> Methylation in Primary Nonmuscle Invasive Bladder Cancer. Disease Markers, 2015, 2015, 1-6.	0.6	8
82	Pre-Clinical Efficacy and Safety Evaluation of Human Amniotic Fluid-Derived Stem Cell Injection in a Mouse Model of Urinary Incontinence. Yonsei Medical Journal, 2015, 56, 648.	0.9	11
83	Comparative analysis of benign prostatic hyperplasia management by urologists and nonurologists: A Korean nationwide health insurance database study. Korean Journal of Urology, 2015, 56, 233.	1.2	10
84	Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH. Annals of Surgical Oncology, 2015, 22, 2439-2445.	0.7	15
85	Assess the expression of ubiquitin specific protease USP2a for bladder cancer diagnosis. BMC Urology, 2015, 15, 80.	0.6	12
86	Prognostic Significance of CREB-Binding Protein and CD81 Expression in Primary High Grade Non-Muscle Invasive Bladder Cancer: Identification of Novel Biomarkers for Bladder Cancer Using Antibody Microarray. PLoS ONE, 2015, 10, e0125405.	1.1	18
87	Urinary MicroRNAs of Prostate Cancer: Virus-Encoded hsv1-miRH18 and hsv2-miR-H9-5p Could Be Valuable Diagnostic Markers. International Neurourology Journal, 2015, 19, 74-84.	0.5	40
88	Effects of Previous or Synchronous Non-Muscle Invasive Bladder Cancer on Clinical Results after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multi-Institutional Study. Urology Journal, 2015, 12, 2233-9.	0.3	9
89	Role of 1,25-Dihydroxy Vitamin D ₃ and Parathyroid Hormone in Urinary Calcium Excretion in Calcium Stone Formers. Yonsei Medical Journal, 2014, 55, 1326.	0.9	13
90	Effect of Renal Insufficiency on Stone Recurrence in Patients with Urolithiasis. Journal of Korean Medical Science, 2014, 29, 1132.	1.1	13

#	Article	IF	CITATIONS
91	Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2. Journal of Korean Medical Science, 2014, 29, 351.	1.1	29
92	Impact of Transobturator Tape Treatment on Overactive Bladder Symptoms, Particularly Nocturia, in Patients With Mixed Urinary Incontinence. Korean Journal of Urology, 2014, 55, 520.	1.2	3
93	Distinct Metabolic Characteristics and Risk of Stone Recurrence in Patients With Multiple Stones at the First-time Presentation. Urology, 2014, 84, 274-278.	0.5	4
94	The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non–muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 458-465.	0.8	9
95	Antiangiogenic Therapy with Human Apolipoprotein(a) Kringle V and Paclitaxel in a Human Ovarian Cancer Mouse Model. Translational Oncology, 2014, 7, 368-376.	1.7	6
96	Hypertriglyceridemia Is Associated With Increased Risk for Stone Recurrence in Patients With Urolithiasis. Urology, 2014, 84, 766-771.	0.5	21
97	Investigational cell cycle inhibitors in clinical trials for bladder cancer. Expert Opinion on Investigational Drugs, 2013, 22, 369-377.	1.9	13
98	Role of the Epithelial-Mesenchymal Transition in Bladder Cancer: From Prognosis to Therapeutic Target. Korean Journal of Urology, 2013, 54, 645.	1.2	74
99	Cell-Free microRNA-214 From Urine as a Biomarker for Non-Muscle-Invasive Bladder Cancer. Korean Journal of Urology, 2013, 54, 791.	1.2	59
100	Decreased <i>DBC1 </i> Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer. Korean Journal of Urology, 2013, 54, 631.	1.2	8
101	Pyrosequencing Analysis of APCMethylation Level in Human Prostate Tissues: A Molecular Marker for Prostate Cancer. Korean Journal of Urology, 2013, 54, 194.	1.2	6
102	Diagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer. Journal of Korean Medical Science, 2013, 28, 1796.	1.1	0
103	Locally recurrent penile apocrine carcinoma initially diagnosed as metastatic adenocarcinoma of colon. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2013, 25, 777-80.	0.7	1
104	Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. International Journal of Oncology, 2012, 41, 1871-1878.	1.4	134
105	Docetaxel-Induced Fatal Interstitial Pneumonitis in a Patient with Castration-Resistant Prostate Cancer. Korean Journal of Urology, 2012, 53, 371.	1.2	10
106	Usefulness of a Combined Approach of T1-Weighted, T2-Weighted, Dynamic Contrast-Enhanced, and Diffusion-Weighted Imaging in Prostate Cancer. Korean Journal of Urology, 2012, 53, 830.	1.2	10
107	Tubal Buccal Mucosa Graft without Anastomosis of the Proximal Urethra for Long Segment Posterior Urethral Defect Repair. Korean Journal of Urology, 2012, 53, 737.	1.2	1
108	DNA Methylation of <i> GSTP1 </i> in Human Prostate Tissues: Pyrosequencing Analysis. Korean Journal of Urology, 2012, 53, 200.	1.2	17

#	Article	IF	Citations
109	Elevated Insulin and Insulin Resistance Are Associated with the Advanced Pathological Stage of Prostate Cancer in Korean Population. Journal of Korean Medical Science, 2012, 27, 1079.	1.1	17
110	Generation of 1E8 Single Chain Fv-Fc Construct Against Human CD59. Immune Network, 2012, 12, 33.	1.6	3
111	FAM70Bas a Novel Prognostic Marker for Cancer Progression and Cancer-Specific Death in Muscle-Invasive Bladder Cancer. Korean Journal of Urology, 2012, 53, 598.	1.2	8
112	A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder Cancer. Molecular Medicine, 2011, 17, 478-485.	1.9	60
113	Prostate Size Correlates with Fasting Blood Glucose in Non-Diabetic Benign Prostatic Hyperplasia Patients with Normal Testosterone Levels. Journal of Korean Medical Science, 2011, 26, 1214.	1.1	28
114	<i>GSTM1</i> Tissue Genotype as a Recurrence Predictor in Non-muscle Invasive Bladder Cancer. Journal of Korean Medical Science, 2011, 26, 231.	1.1	15
115	Expectant Management of Ureter Stones: Outcome and Clinical Factors of Spontaneous Passage in a Single Institution's Experience. Korean Journal of Urology, 2011, 52, 847.	1.2	30
116	<i>GSTT1</i> as a Prognosticator for Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer. Disease Markers, 2010, 29, 81-87.	0.6	11
117	Phosphaturia as a Promising Predictor of Recurrent Stone Formation in Patients with Urolithiasis. Korean Journal of Urology, 2010, 51, 54.	1.2	11
118	Comparison of Metabolic Risk Factors in Urolithiasis Patients according to Family History. Korean Journal of Urology, 2010, 51, 50.	1.2	11
119	Influence of Obesity on Short-term Surgical Outcome of the Transobturator Tape Procedure in Patients with Stress Urinary Incontinence. International Neurourology Journal, 2010, 14, 13.	0.5	23
120	Granular Cell Tumor of the Urinary Bladder. Korean Journal of Urology, 2010, 51, 291.	1.2	14
121	mRNA Expression of S100A8 as a Prognostic Marker for Progression of Non-Muscle-Invasive Bladder Cancer. Korean Journal of Urology, 2010, 51, 15.	1.2	20
122	Alpha-Methylacyl-Coenzyme A Racemase-Expressing Urachal Adenocarcinoma of the Abdominal Wall. Korean Journal of Urology, 2010, 51, 498.	1.2	7
123	Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Molecular Cancer, 2010, 9, 3.	7.9	309
124	Sodium Restriction as Initial Conservative Treatment for Urinary Stone Disease. Journal of Urology, 2010, 184, 1372-1376.	0.2	15
125	Acute and Serious Myositis with Abscess in Thigh Muscle after Transobturator Tape Implantation. International Neurourology Journal, 2010, 14, 182.	0.5	5
126	Effects of Metabolic Syndrome on Chronic Kidney Disease. Korean Journal of Urology, 2009, 50, 261.	1.2	2

#	Article	IF	Citations
127	Comparison of Clinico-Metabolic Characteristics between Calcium Oxalate and Uric Acid Stone Formers. Korean Journal of Urology, 2009, 50, 897.	1.2	0
128	The Comparison between Transperineal and Transrectal Ultrasound-Guided Prostate Needle Biopsy. Korean Journal of Urology, 2009, 50, 119.	1.2	4
129	Changes in Urinary Lithogenic Features Over Time in Patients With Urolithiasis. Urology, 2009, 74, 51-55.	0.5	8
130	Forkhead box O-class 1 and Forkhead box $G1$ as Prognostic Markers for Bladder Cancer. Journal of Korean Medical Science, 2009, 24, 468.	1.1	32
131	The Relationship between RUNX3 Inactivation and Its Pathological Features in Renal Cell Carcinoma. Korean Journal of Urology, 2009, 50, 432.	1.2	2
132	Impact of Obesity in Patients With Urolithiasis and its Prognostic Usefulness in Stone Recurrence. Journal of Urology, 2008, 179, 570-574.	0.2	84
133	A Primary Large Cell Neuroendocrine Carcinoma of the Urinary Bladder in a 19-year-old Man. Korean Journal of Urology, 2008, 49, 647.	0.2	0
134	A Large Stone in the Dilated Left Seminal Vesicle: Laparoscopic Removal and Partial Seminal Vesiculectomy. Korean Journal of Urology, 2008, 49, 656.	0.2	9
135	Anticancer Effect of Magnolia officinalis' Extract on N-butyl-N-(4-hydroxybutyl) Nitrosamine Induced Bladder Cancer in Mice. Korean Journal of Urology, 2008, 49, 682.	0.2	0
136	Changes in Voiding Patterns after Transobturator Tape Operation in Female Patients with Stress Urinary Incontinence. Korean Journal of Urology, 2008, 49, 609.	0.2	0
137	Clinical Significance of the Expression of Gli2 and Gli3 in Bladder Cancer. Korean Journal of Urology, 2008, 49, 696.	0.2	0
138	Utility of Smo as a Prognostic Marker for Human Bladder Tumors. Korean Journal of Urology, 2007, 48, 997.	0.2	4
139	The Expression and Clinical Implications of Forkhead Trasnscription Factor FKHR (FOXO1) in Human Bladder Cancer. Korean Journal of Urology, 2007, 48, 396.	0.2	0